HealthEquity, Inc. (NASDAQ:HQY) Stock Has Consensus Target Price of $112.20

HealthEquity, Inc. (NASDAQ:HQY) has received an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $112.20.

Several research analysts have recently weighed in on the stock. Wells Fargo & Company set a $111.00 price objective on shares of HealthEquity in a report on Monday, June 1st. Royal Bank Of Canada raised their target price on shares of HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. BTIG Research reaffirmed a “buy” rating and issued a $115.00 target price on shares of HealthEquity in a research report on Friday, August 28th. Wall Street Zen lowered shares of HealthEquity from a “buy” rating to a “hold” rating in a research note on Saturday, September 5th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on HealthEquity from $135.00 to $142.00 and gave the company a “buy” rating in a report on Monday, August 31st.

HealthEquity Trading Down 2.0%

HealthEquity stock opened at $88.60 on Tuesday. HealthEquity has a one year low of $72.76 and a one year high of $107.62. The business’s fifty day moving average is $99.24 and its 200 day moving average is $90.32. The stock has a market capitalization of $7.33 billion, a PE ratio of 31.99, a price-to-earnings-growth ratio of 1.45 and a beta of 0.22. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.99 and a quick ratio of 2.99.

HealthEquity (NASDAQ:HQY) last issued its earnings results on Thursday, August 27th. The company reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.05. The business had revenue of $350.73 million during the quarter, compared to analyst estimates of $349.22 million. HealthEquity had a return on equity of 15.33% and a net margin of 17.36%.The business’s revenue for the quarter was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. On average, sell-side analysts predict that HealthEquity will post 3.93 EPS for the current year.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Director Adrian T. Dillon sold 7,632 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total value of $798,383.52. Following the transaction, the director directly owned 62,395 shares of the company’s stock, valued at approximately $6,527,140.95. This trade represents a 10.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Fiore sold 2,354 shares of the business’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $95.00, for a total value of $223,630.00. Following the sale, the executive vice president owned 52,244 shares of the company’s stock, valued at approximately $4,963,180. This represents a 4.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,456 shares of company stock valued at $1,256,664 in the last ninety days. 1.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On HealthEquity

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Oxbow Advisors LLC purchased a new stake in shares of HealthEquity in the 1st quarter worth $3,147,000. Maridea Wealth Management LLC bought a new position in HealthEquity in the 2nd quarter worth $2,753,000. Deutsche Bank AG purchased a new position in HealthEquity during the second quarter valued at $11,986,000. Bamco Inc. NY bought a new stake in HealthEquity during the second quarter valued at about $67,776,000. Finally, Westfield Capital Management Co. LP grew its holdings in HealthEquity by 13.7% during the fourth quarter. Westfield Capital Management Co. LP now owns 1,952,452 shares of the company’s stock valued at $178,864,000 after purchasing an additional 235,794 shares during the period. Hedge funds and other institutional investors own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services for consumer-directed benefits and healthcare savings accounts. The company helps employers, benefits advisors and individuals manage tax-advantaged accounts, including health savings accounts (HSAs), flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), commuter benefits and other employee benefit programs.

Its offerings include account administration, payment cards, reimbursement services, benefits communication, compliance support, healthcare spending tools and investment options for eligible HSA funds.